Ubiquitin Proteasome System and Molecular Signatures of Alzheimer's Disease - Tools are needed to establish the etiology of Alzheimer’s disease (AD), whose signatures appear before the
disease presents. Early in AD is ubiquitylation of misfolded proteins; those not degraded by the proteasome can
form neurofibrillary tangles such as β-amyloid or tau protein aggregates. Ubiquitin (Ub)-mediated signaling plays
a central role in protein degradation, and a first step in neurodegeneration is a change in ubiquitylation patterns,
particularly, that of poly-Ub chains attached to proteins. Development of sensitive methods to detect these
ubiquitylation signatures will be a major advance in AD drug discovery and diagnosis. Poly-Ub chains are formed
utilizing all seven lysines, as well as the N-terminus of ubiquitin, suggesting that these chains encode much
information. Each linkage, including mono-Ub, signals a characteristic outcome for the protein; Ub chain
architecture is the subject of this project. The best characterized Ub types are Lys48 (K48) and Lys63 (K63)
linkages; K48- and K11-linked chains target proteins for degradation by the proteasome while K63-linked chains
regulate receptor endocytosis, DNA repair, oxidative stress and other pathways. Specific functions for other
linkages are currently under study. Two impediments to understanding specific poly-ubiquitylated protein
structures and functions are: 1) while most proteins at some point are ubiquitylated, at any given time the
ubiquitylated fraction may be a small percentage of total cell protein; and 2) within the pool of ubiquitylated
protein, any particular linkage may be rare. Further, very few tools are available for specific detection or
purification of ubiquitylated proteins with specific poly-Ub linkages. In phase I, Ub Binding Domains (UBDs)
selective for atypical poly-Ub (K6/K11/K27/K29/K33) were identified using a 150 UBD protein microarray chip
developed by Dr Mark Bedford, M D Anderson Cancer Center. Also identified was the UBD with the highest
selectivity for K48 linked poly-ubiquitylated proteins. In addition, KD values and specificity for novel UBDs were
determined using SPR, fulfilling the aims. In Phase II LifeSensors will engineer the UBD domains to improve
affinity and selectivity using UBD domains called TUBEs (Tandem Ubiquitin Binding Entities); these include
nonselective as well as Linear [M1], K48- and K63-specific TUBEs. Dr. Bedford will continue his collaboration in
Phase II. Also participating in Phase II will be Dr. David Fushman, University of Maryland, who has pioneered
solution NMR methods to study poly-Ub chains. the Phase II project entails establishing the poly-Ub chain linkage
selectivity of UBDs identified in Phase I using structure-based protein engineering and generating poly-Ub chain-
selective TUBEs to improve affinity, enhance avidity of binding, and improve linkage selectivity. Finally, these
novel atypical poly-Ub TUBEs will be validated for application in neuronal cells by simulating proteinopathies.
.